Biologic response modifiers in the management of superficial bladder cancer
For the treatment of existing transitional-cell carcinoma or for prophylaxis of recurrent disease, intravesical therapy should be chosen according to stage. Papillary disease (stages Ta, Tl) may be treated effectively either with an alkylating agent or with bacillus Calmette-Guérin (BCG). BCG is the...
Gespeichert in:
| Veröffentlicht in: | World journal of urology 1997-04, Vol.15 (2), p.96-102 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 102 |
|---|---|
| container_issue | 2 |
| container_start_page | 96 |
| container_title | World journal of urology |
| container_volume | 15 |
| creator | Serels, S Fleischmann, J |
| description | For the treatment of existing transitional-cell carcinoma or for prophylaxis of recurrent disease, intravesical therapy should be chosen according to stage. Papillary disease (stages Ta, Tl) may be treated effectively either with an alkylating agent or with bacillus Calmette-Guérin (BCG). BCG is the agent of choice for the treatment of Hat carcinoma in situ (Tis), with the recommended treatment course comprising 12 weekly and 12 monthly instillations. Intravesical interferon and many of the other biologic response modifiers mentioned herein may be effective for patients with Ta disease who have failed BCG therapy. |
| doi_str_mv | 10.1007/BF02201979 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79003510</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79003510</sourcerecordid><originalsourceid>FETCH-LOGICAL-c270t-eccb632c7fc56aad312f258105b17a0f0fd91162f5cd1cbf79b795b548d4c4d63</originalsourceid><addsrcrecordid>eNp90U1Lw0AQBuBFlFqrF-9CQPAgRGe_stmjLVbFghc9h81-1JUkG3ebg__elBYFD54GhoeXYV6EzjHcYABxO18CIYClkAdoihmleSlIcYimIAjLmSzpMTpJ6QMAiwL4BE0kZqyU5RQ9z31owtrrLNrUhy7ZrA3GO29jynyXbd7HherU2ra222TBZWnobXRee9VkdaOMsTHTqtM2nqIjp5pkz_Zzht6W96-Lx3z18vC0uFvlmgjY5FbruqBEC6d5oZShmDjCSwy8xkKBA2ckxgVxXBusaydkLSSvOSsN08wUdIaudrl9DJ-DTZuq9UnbplGdDUOqhASgHMMIL__AjzDEbrytIoXkBZOiFP8pDERgVjKyzbreKR1DStG6qo--VfFrRNW2heq3hRFf7COHurXmh-7fTr8Bq6yANg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1027148420</pqid></control><display><type>article</type><title>Biologic response modifiers in the management of superficial bladder cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Serels, S ; Fleischmann, J</creator><creatorcontrib>Serels, S ; Fleischmann, J</creatorcontrib><description>For the treatment of existing transitional-cell carcinoma or for prophylaxis of recurrent disease, intravesical therapy should be chosen according to stage. Papillary disease (stages Ta, Tl) may be treated effectively either with an alkylating agent or with bacillus Calmette-Guérin (BCG). BCG is the agent of choice for the treatment of Hat carcinoma in situ (Tis), with the recommended treatment course comprising 12 weekly and 12 monthly instillations. Intravesical interferon and many of the other biologic response modifiers mentioned herein may be effective for patients with Ta disease who have failed BCG therapy.</description><identifier>ISSN: 0724-4983</identifier><identifier>EISSN: 1433-8726</identifier><identifier>DOI: 10.1007/BF02201979</identifier><identifier>PMID: 9144898</identifier><language>eng</language><publisher>Germany: Springer Nature B.V</publisher><subject>Administration, Intravesical ; Bladder cancer ; Cancer ; Humans ; Immunologic Factors - therapeutic use ; Immunotherapy ; Interferon ; Prophylaxis ; Urinary Bladder Neoplasms - therapy</subject><ispartof>World journal of urology, 1997-04, Vol.15 (2), p.96-102</ispartof><rights>Springer-Verlag 1997.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c270t-eccb632c7fc56aad312f258105b17a0f0fd91162f5cd1cbf79b795b548d4c4d63</citedby><cites>FETCH-LOGICAL-c270t-eccb632c7fc56aad312f258105b17a0f0fd91162f5cd1cbf79b795b548d4c4d63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9144898$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Serels, S</creatorcontrib><creatorcontrib>Fleischmann, J</creatorcontrib><title>Biologic response modifiers in the management of superficial bladder cancer</title><title>World journal of urology</title><addtitle>World J Urol</addtitle><description>For the treatment of existing transitional-cell carcinoma or for prophylaxis of recurrent disease, intravesical therapy should be chosen according to stage. Papillary disease (stages Ta, Tl) may be treated effectively either with an alkylating agent or with bacillus Calmette-Guérin (BCG). BCG is the agent of choice for the treatment of Hat carcinoma in situ (Tis), with the recommended treatment course comprising 12 weekly and 12 monthly instillations. Intravesical interferon and many of the other biologic response modifiers mentioned herein may be effective for patients with Ta disease who have failed BCG therapy.</description><subject>Administration, Intravesical</subject><subject>Bladder cancer</subject><subject>Cancer</subject><subject>Humans</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Immunotherapy</subject><subject>Interferon</subject><subject>Prophylaxis</subject><subject>Urinary Bladder Neoplasms - therapy</subject><issn>0724-4983</issn><issn>1433-8726</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp90U1Lw0AQBuBFlFqrF-9CQPAgRGe_stmjLVbFghc9h81-1JUkG3ebg__elBYFD54GhoeXYV6EzjHcYABxO18CIYClkAdoihmleSlIcYimIAjLmSzpMTpJ6QMAiwL4BE0kZqyU5RQ9z31owtrrLNrUhy7ZrA3GO29jynyXbd7HherU2ra222TBZWnobXRee9VkdaOMsTHTqtM2nqIjp5pkz_Zzht6W96-Lx3z18vC0uFvlmgjY5FbruqBEC6d5oZShmDjCSwy8xkKBA2ckxgVxXBusaydkLSSvOSsN08wUdIaudrl9DJ-DTZuq9UnbplGdDUOqhASgHMMIL__AjzDEbrytIoXkBZOiFP8pDERgVjKyzbreKR1DStG6qo--VfFrRNW2heq3hRFf7COHurXmh-7fTr8Bq6yANg</recordid><startdate>19970401</startdate><enddate>19970401</enddate><creator>Serels, S</creator><creator>Fleischmann, J</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>19970401</creationdate><title>Biologic response modifiers in the management of superficial bladder cancer</title><author>Serels, S ; Fleischmann, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c270t-eccb632c7fc56aad312f258105b17a0f0fd91162f5cd1cbf79b795b548d4c4d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Administration, Intravesical</topic><topic>Bladder cancer</topic><topic>Cancer</topic><topic>Humans</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Immunotherapy</topic><topic>Interferon</topic><topic>Prophylaxis</topic><topic>Urinary Bladder Neoplasms - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Serels, S</creatorcontrib><creatorcontrib>Fleischmann, J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>World journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Serels, S</au><au>Fleischmann, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biologic response modifiers in the management of superficial bladder cancer</atitle><jtitle>World journal of urology</jtitle><addtitle>World J Urol</addtitle><date>1997-04-01</date><risdate>1997</risdate><volume>15</volume><issue>2</issue><spage>96</spage><epage>102</epage><pages>96-102</pages><issn>0724-4983</issn><eissn>1433-8726</eissn><abstract>For the treatment of existing transitional-cell carcinoma or for prophylaxis of recurrent disease, intravesical therapy should be chosen according to stage. Papillary disease (stages Ta, Tl) may be treated effectively either with an alkylating agent or with bacillus Calmette-Guérin (BCG). BCG is the agent of choice for the treatment of Hat carcinoma in situ (Tis), with the recommended treatment course comprising 12 weekly and 12 monthly instillations. Intravesical interferon and many of the other biologic response modifiers mentioned herein may be effective for patients with Ta disease who have failed BCG therapy.</abstract><cop>Germany</cop><pub>Springer Nature B.V</pub><pmid>9144898</pmid><doi>10.1007/BF02201979</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0724-4983 |
| ispartof | World journal of urology, 1997-04, Vol.15 (2), p.96-102 |
| issn | 0724-4983 1433-8726 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79003510 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Administration, Intravesical Bladder cancer Cancer Humans Immunologic Factors - therapeutic use Immunotherapy Interferon Prophylaxis Urinary Bladder Neoplasms - therapy |
| title | Biologic response modifiers in the management of superficial bladder cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T09%3A56%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biologic%20response%20modifiers%20in%20the%20management%20of%20superficial%20bladder%20cancer&rft.jtitle=World%20journal%20of%20urology&rft.au=Serels,%20S&rft.date=1997-04-01&rft.volume=15&rft.issue=2&rft.spage=96&rft.epage=102&rft.pages=96-102&rft.issn=0724-4983&rft.eissn=1433-8726&rft_id=info:doi/10.1007/BF02201979&rft_dat=%3Cproquest_cross%3E79003510%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1027148420&rft_id=info:pmid/9144898&rfr_iscdi=true |